$13.90
+0.18 (+1.31%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where CMPS is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
8 interventional · 1 observational · 3 with posted results
Held by 15 tracked-famous managers (TWO SIGMA INVESTMENTS, LP, MARSHALL WACE, LLP, Point72 Asset Management, L.P., RENAISSANCE TECHNOLOGIES LLC, CITADEL ADVISORS LLC, +10 more) · FINRA short interest 3.6 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress DisorderNCT07570654COMP360 25 mg versus COMP360 1 mg change from Baseline to Week 8 in CAPS-5 total severity scoreRandomized · Quadruple-masked · Treatment | Phase 2/3 | Recruiting | Drug: COMP360 psilocybin | PTSD - Post Traumatic Stress Disorder, PTSD, PTSD Symptoms, PTSD, Post Traumatic Stress Disorder | 300 | Nov 2028 | ≤ 834 d | 2026-08-18 |
| Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRDNCT05711940COMP360 25 mg versus COMP360 1 mg for the change from baseline in MADRS total score.Randomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Psilocybin | Treatment Resistant Depression | 572 | 2025-11-13actual | — | 2026-08-10 |
| A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive DisorderNCT05733546Safety and tolerability of COMP360 PsilocybinRandomized · Quadruple-masked · Treatment | Phase 2 | Active, not recruiting | Drug: Psilocybin | Major Depressive Disorder | 102 | Sep 2025 | — | 2025-08-19 |
| Efficacy, Safety, and Tolerability of COMP360 in Participants With TRDNCT05624268COMP360 25 mg versus placebo for the change from baseline in MADRS total scoreRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Psilocybin | Treatment Resistant Depression | 258 | 2025-05-28actual | — | 2026-08-10 |
| Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept StudyNCT05481736Change from baseline in the Eating Disorder Examination (EDE) global scoreRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: Psilocybin | Anorexia Nervosa | 32 | 2024-11-18actual | — | 2024-12-04 |
| The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress DisorderNCT05312151results2025-06-13Number of Participants With Any Treatment-emergent Adverse Event (TEAE)Open-label · TreatmentStudy Protocol: v5.0 ↗ · Study Protocol: v4.0 ↗ · Study Protocol: v3.0 ↗ · Study Protocol: v2.0 ↗ · Study Protocol: v1.0 ↗ · Statistical Analysis Plan ↗ · Informed Consent Form ↗ | Phase 2 | Completed | Drug: Psilocybin | Post Traumatic Stress Disorder | 22 | 2024-02-12actual | — | 2025-06-13 |
| Long Term Follow Up Study to COMP 001 And COMP 003 Trials (P-TRD LTFU)NCT04519957observationalLong-term efficacy of psilocybin | — | Completed | — | Treatment Resistant Depression | 66 | 2022-08-11actual | — | 2022-09-22 |
| The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant DepressionNCT04739865results2023-11-09Improvement in Depressive SymptomsOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Psilocybin | Treatment Resistant Depression | 19 | 2021-10-14actual | — | 2023-11-09 |
| The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant DepressionNCT03775200results2023-04-24Montgomery Asberg Depression Rating Scale (MADRS) Change From Baseline to Week 3Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Psilocybin | Treatment Resistant Depression | 233 | 2021-07-30actual | — | 2023-04-24 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19